LRP3 and atrial fibrillation: Although the literature about serum biomarkers and their association with AF in diabetic patients is limited, an animal study (diabetic rabbits) by Wu et al. [124] established that increased LRP3-inflammasome/caspase-1/Gal-3 pathway activity impacts atrial remodeling and is therefore implicated in AF induced by diabetes.